Evotec announced research chief exit while Evotec stock gains 2.85 percent

Published on 10/13/2026 at 09:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock costs EUR 2.53 on October 13, 2026 versus the Xetra close at EUR 2.46. Second-quarter revenue fell 16.21 percent to EUR 143.48 million.

Key points in brief

Evotec stock was at EUR 2.53 at Lang & Schwarz on October 13, 2026, up 2.85 percent versus the Xetra close of EUR 2.46.
Revenue fell 16.21 percent year over year to EUR 143.48 million in the second quarter of 2026.
Evotec expects 2026 revenue of EUR 570 million to EUR 610 million and an adjusted EBITDA loss of EUR 70 million to EUR 105 million.
Evotec's next scheduled report is for the third quarter on November 5, 2026.

Extreme Makroaufnahme einer leuchtend blauen kristallinen Molekülstruktur — Makroaufnahme einer kristallinen Molekülstruktur verweist auf die Wirkstoffforschung von Evotec SE, ISIN DE0005664809, leuchtendes Blau, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) was trading at EUR 2.53 at Lang & Schwarz on October 13, 2026 at 9:30 a.m. CEST, up 2.85 percent versus the Xetra close of EUR 2.46 on October 12, 2026. The company had announced the departure of research chief Cord Dohrmann effective September 30, 2026, according to EQS Group.

Three dated turning points

On August 12, 2026, Evotec cut its full-year revenue guidance to EUR 570 million to EUR 610 million from EUR 700 million to EUR 780 million and shifted adjusted EBITDA guidance from a profit of EUR 0 million to EUR 40 million to a loss of EUR 70 million to EUR 105 million, as reported by NadirAlpha. Evotec reported second-quarter 2026 revenue of EUR 143.48 million, down 16.21 percent from EUR 171.24 million a year earlier, according to finanzen.ch on October 12, 2026. On September 29, 2026, Dohrmann's 16-year tenure as chief scientific officer ended, while Evotec began searching for a successor.

What does November 5 test?

Evotec is scheduled to publish its third-quarter 2026 report on November 5, 2026, a date listed by comdirect. The report will show whether the company is moving toward its reduced revenue range of EUR 570 million to EUR 610 million and whether the adjusted EBITDA loss remains within the EUR 70 million to EUR 105 million guidance range.

Analyst caution meets a low base

Berenberg kept its Hold rating and EUR 3.60 price target on September 25, 2026 after a discussion with Chief Executive Christian Wojczewski, according to finanzen.ch. The bank cited commercial repositioning, delayed milestones and limited visibility on revenue development. The target is EUR 1.07 above the current Lang & Schwarz price, but the comparison uses different trading venues and is therefore not expressed as a percentage.

Stock remains near its yearly low

The October 12 Xetra close of EUR 2.46 was also the 52-week low cited in the Xetra market report, while the 52-week high stood at EUR 7.30. At EUR 2.53, the Lang & Schwarz quote is EUR 0.07 above that close, leaving the stock close to its yearly floor while the operating outlook remains under pressure.

Evotec stock price and next date

Evotec was trading at EUR 2.53 at Lang & Schwarz on October 13, 2026 at 9:30 a.m. CEST, plus 2.85 percent versus the Xetra close of EUR 2.46 on October 12, 2026. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.